{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:19:14Z","timestamp":1770999554183,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00223-009-9294-y","type":"journal-article","created":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T17:45:50Z","timestamp":1255023950000},"page":"389-397","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women"],"prefix":"10.1007","volume":"85","author":[{"given":"Yoon-Sok","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Kil","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Yeon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il-Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghi-Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo-Il","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Hwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ho","family":"Shong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Won","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Koo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yil-Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,9]]},"reference":[{"key":"9294_CR1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","volume":"2","author":"C Cooper","year":"1992","unstructured":"Cooper C, Compion G, Melton LJ (1992) Hip fractures in the elderly: a worldwide projection. Osteoporos Int 2:285\u2013289","journal-title":"Osteoporos Int"},{"key":"9294_CR2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"IC Chesnut","year":"2004","unstructured":"Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"9294_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4065\/80.3.379","volume":"80","author":"S Epstein","year":"2005","unstructured":"Epstein S (2005) The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80:379\u2013388","journal-title":"Mayo Clin Proc"},{"key":"9294_CR4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"9294_CR5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437\u20131443","journal-title":"N Engl J Med"},{"key":"9294_CR6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"9294_CR7","first-page":"1","volume":"921","author":"World Health Organization","year":"2003","unstructured":"World Health Organization (2003) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921:1\u2013164","journal-title":"World Health Organ Tech Rep Ser"},{"key":"9294_CR8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","volume":"38","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2\u2013S6","journal-title":"Bone"},{"key":"9294_CR9","first-page":"S529","volume":"15 Suppl 1","author":"C Lombas","year":"2001","unstructured":"Lombas C, Hakim C, Znachetta JR (2001) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 Suppl 1:S529","journal-title":"J Bone Miner Res"},{"key":"9294_CR10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pec.2004.08.006","volume":"57","author":"KH Jahng","year":"2005","unstructured":"Jahng KH, Martin LR, Golin CE, DiMatteo MR (2005) Preferences for medical collaboration: patient\u2013physician congruence and patient outcomes. Patient Educ Couns 57:308\u2013314","journal-title":"Patient Educ Couns"},{"key":"9294_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","volume":"48","author":"D Kendler","year":"2004","unstructured":"Kendler D, Kung AW, Fuleihan Gel H, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243\u2013251","journal-title":"Maturitas"},{"key":"9294_CR12","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","volume":"24","author":"JA Simon","year":"2002","unstructured":"Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871\u20131886","journal-title":"Clin Ther"},{"key":"9294_CR13","first-page":"S45","volume":"16 Suppl 3","author":"R Bartl","year":"2005","unstructured":"Bartl R, Goette S, Hadji P, Hammerschmidt T (2005) Persistence and compliance with daily and weekly administered bisphophonates for osteoporosis treatment in Germany. Osteoporos Int 16 Suppl 3:S45","journal-title":"Osteoporos Int"},{"key":"9294_CR14","first-page":"S448","volume":"19 Suppl 1","author":"JA Cramer","year":"2004","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Suppapanya N (2004) Does dosing regimen impact persistence with bisphosphonate theapy among postmenopausal osteoporotic women. J Bone Miner Res 19 Suppl 1:S448","journal-title":"J Bone Miner Res"},{"key":"9294_CR15","first-page":"S513","volume":"50","author":"MP Ettinger","year":"2004","unstructured":"Ettinger MP, Gallagher R, Amonkar M, Mahoney PM, Gilbride J (2004) Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 50:S513","journal-title":"Arthritis Rheum"},{"key":"9294_CR16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"9294_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303\u2013310","journal-title":"Joint Bone Spine"},{"key":"9294_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/biomet\/56.1.75","volume":"56","author":"JJ Gart","year":"1969","unstructured":"Gart JJ (1969) An exact test for comparing matched proportions in cross-over designs. Biometrika 56:75\u201380","journal-title":"Biometrika"},{"key":"9294_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2307\/2346652","volume":"30","author":"RJ Prescott","year":"1981","unstructured":"Prescott RJ (1981) The comparison of success rates in cross-over trials in the presence of an order effect. Appl Stat 30:9\u201315","journal-title":"Appl Stat"},{"key":"9294_CR20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296\u20131310","journal-title":"Clin Ther"},{"key":"9294_CR21","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/S0149-2918(03)80222-9","volume":"25","author":"A Richter","year":"2003","unstructured":"Richter A, Anton SE, Koch P, Dennett SL (2003) The impact of reducing dose frequency on health outcomes. Clin Ther 25:2306\u20132335","journal-title":"Clin Ther"},{"key":"9294_CR22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00198-008-0772-2","volume":"20","author":"JR Curtis","year":"2009","unstructured":"Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E (2009) Risedronate and Alendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int 20:973\u2013978","journal-title":"Osteoporos Int"},{"key":"9294_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00774-006-0739-3","volume":"25","author":"J Takada","year":"2007","unstructured":"Takada J, Iba K, Imoto K, Yamashita T (2007) Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 25:142\u2013146","journal-title":"J Bone Miner Metab"},{"key":"9294_CR24","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0149-2918(01)80116-8","volume":"23","author":"EM Umland","year":"2001","unstructured":"Umland EM, Boyce EG (2001) Risedronate: a new oral bisphosphonate. Clin Ther 23:1409\u20131421","journal-title":"Clin Ther"},{"key":"9294_CR25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00774-007-0768-6","volume":"25","author":"M Kamatari","year":"2007","unstructured":"Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302\u2013309","journal-title":"J Bone Miner Metab"},{"key":"9294_CR26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1185\/030079904125003548","volume":"20","author":"JA Eisman","year":"2004","unstructured":"Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699\u2013705","journal-title":"Curr Med Res Opin"},{"key":"9294_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"B Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259\u2013262","journal-title":"Osteoporos Int"},{"key":"9294_CR28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","volume":"119","author":"FL Lanza","year":"2000","unstructured":"Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:631\u2013638","journal-title":"Gastroenterology"},{"key":"9294_CR29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914\u2013921","journal-title":"Osteoporos Int"},{"key":"9294_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209\u2013216","journal-title":"Am J Med"},{"key":"9294_CR31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","volume":"15","author":"PD Delmas","year":"2004","unstructured":"Delmas PD, Recker RR, Chesnut CH III, Skag A, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792\u2013798","journal-title":"Osteoporos Int"},{"key":"9294_CR32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"9294_CR33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","volume":"44","author":"ST Harris","year":"2009","unstructured":"Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The Evaluation of Ibandronate Efficacy (VIBE) database fracture study. Bone 44:758\u2013765","journal-title":"Bone"},{"key":"9294_CR34","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896\u2013905","journal-title":"Int J Clin Pract"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-009-9294-y.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T03:07:37Z","timestamp":1554606457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-009-9294-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["9294"],"URL":"https:\/\/doi.org\/10.1007\/s00223-009-9294-y","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,9]]}}}